“The IDEAL trial - a study protocol for a phase III randomized, double-blinded clinical trial assessing the ultra-short antibiotic prophylaxis of Isoniazid and Rifapentine in non-immunosuppressed patients with newly diagnosed latent tuberculosis” (2020) Principles and Practice of Clinical Research, 6(1), pp. 9–14. Available at: https://journal.ppcr.org/index.php/ppcrjournal/article/view/96 (Accessed: 7 May 2024).